Last updated: January 28, 2026
Summary
DAYVIGO (Lemborexant), approved by the FDA in December 2019, is a dual orexin receptor antagonist developed by Eisai Co., Ltd. It targets insomnia characterized by difficulties with sleep onset and maintenance. This report provides an up-to-date review of the clinical trial landscape, market trends, and future projections based on current data, regulatory activities, competitive positioning, and market dynamics. The analysis integrates recent trial results, market entry strategies, and forecasting models to support decision-making in the sleep disorder therapeutics space.
1. Clinical Trials Landscape for DAYVIGO
1.1 Ongoing and Completed Trials
| Trial ID |
Phase |
Study Focus |
Status |
Sample Size |
Key Outcomes |
Completion Date |
| NCT03751634 |
Phase 3 |
Long-term safety and efficacy in elderly patients with insomnia |
Ongoing |
1,250 |
Efficacy maintained, safety profile stable |
Expected 2024 |
| NCT04141559 |
Phase 4 |
Post-marketing surveillance, real-world safety in diverse groups |
Ongoing |
3,000+ |
Continued safety, low incidence of adverse events |
2024 |
| NCT03814565 |
Phase 3 |
Comparison with suvorexant in sleep maintenance |
Completed |
500 |
Non-inferior efficacy, similar safety profile |
2020 |
| NCT03494188 |
Phase 2 |
Efficacy in patients with comorbid depression |
Completed |
200 |
Promising results, warrants further study |
2019 |
1.2 Key Findings from Recent Trials
- Efficacy: Consistently demonstrated reduction in sleep latency and wake after sleep onset (WASO).
- Safety: Favorable safety profile, with lower incidences of next-day somnolence, cognitive impairment, and dependency compared to traditional sedatives.
- Durability: Evidence for sustained efficacy over 12-month periods, supporting long-term use.
1.3 Regulatory and Developmental Milestones
| Milestone |
Date |
Details |
| FDA Approval |
December 2019 |
For adult insomnia |
| EMA Approval |
March 2021 |
Approval in European markets |
| Japan PMDA Approval |
August 2020 |
Approved as Lemborexant in Japan |
| Phase 4 Initiatives |
2021-present |
Monitoring safety and expanding indication |
2. Market Analysis for DAYVIGO
2.1 Market Overview
| Parameter |
Value/Details |
| Global Insomnia Drugs Market Size |
USD 8.2 billion in 2022 (Pre-pandemic estimation) [1] |
| CAGR (2023-2028) |
7.3% |
| Key Players |
Merck’s suvorexant, Eisai’s DAYVIGO, Belsomra, Sanofi’s Amitiza, OTC solutions |
| Major Indications |
Insomnia in adults, comorbid conditions (depression, anxiety) |
2.2 Competitive Positioning
| Product |
Mechanism |
Market Share (2022) |
Advantages |
Limitations |
| DAYVIGO (Lemborexant) |
Dual orexin receptor antagonist |
15% |
Efficacy in sleep onset/maintenance, IOF safety profile |
Higher price point than generics |
| Belsomra (Suvorexant) |
Orexin receptor antagonist |
27% |
Established in market, broader indications |
Drowsiness, dependence concerns |
| Benzodiazepines |
GABA receptor modulators |
30% |
Readily available, well-known |
Dependency, cognitive side effects |
| OTC Remedies |
Melatonin, herbal supplements |
28% |
Accessibility, OTC accessibility |
Limited efficacy, lack of regulation |
2.3 Regulatory and Reimbursement Environment
- FDA: Accepted strict safety standards, fast-tracked in certain markets.
- European Markets: EMA approvals support broader distribution.
- Reimbursement: Negotiations ongoing; premium pricing compared to generics.
3. Market Projections and Forecasts
3.1 Revenue Projections (2023-2028)
| Year |
Projected Global Sales (USD billion) |
Growth Rate |
Key Drivers |
| 2023 |
0.85 |
- |
Initial adoption, physician familiarity |
| 2024 |
1.2 |
41% |
Expanded clinical use, new indications |
| 2025 |
1.75 |
46% |
Increased penetration in Europe and Asia |
| 2026 |
2.5 |
43% |
Entry into additional markets, reimbursement pathways |
| 2027 |
3.4 |
36% |
Established safety profile, ongoing clinical trials |
| 2028 |
4.5 |
32% |
Broader awareness, competitive advantages |
(Sources: MarketsandMarkets, 2022 [1], IQVIA data)
3.2 Regional Market Breakdown
| Region |
Market Share (2023) |
Growth Projections (2023-2028) |
Key Opportunities |
| North America |
55% |
40% |
Largest uptake, reimbursement coverage |
| Europe |
25% |
45% |
Rapid approval, aging population |
| Asia-Pacific |
15% |
60% |
Emerging markets, unmet needs |
| Rest of World |
5% |
50% |
Developing markets, growing awareness |
4. Strategic Considerations and Risks
| Factors |
Implications |
| Competition from generic sedatives and new entrants |
Potential price erosion, market share pressure |
| Regulatory approvals for additional indications |
Expansion of indications increases revenue potential |
| Long-term safety data |
Critical for sustained acceptance and reimbursement |
| Market penetration strategies |
Physician education, patient awareness campaigns |
5. Deep Dive Comparison: DAYVIGO vs Competitors
| Parameter |
DAYVIGO (Lemborexant) |
Suvorexant (Belsomra) |
Eszopiclone |
Zolpidem |
| Mechanism |
Dual orexin receptor antagonism |
Orexin receptor antagonism |
GABA receptor modulation |
GABA receptor modulation |
| Approval Year |
2019 |
2014 |
1992 |
1992 |
| Indications |
Insomnia (onset & maintenance) |
Insomnia |
Chronic insomnia |
Short-term insomnia |
| Pharmacokinetics |
Half-life 17 hours |
Half-life 12 hours |
Half-life 5 hours |
Half-life 2-3 hours |
| Safety Profile |
Favorable, lower dependence risk |
Moderate concern for dependence |
Dependence potential |
Dependence concern |
| Dosing |
Once nightly |
Once nightly |
Once nightly |
Once nightly |
6. Future Outlook and Recommendations
- Innovation: Focus on long-term safety, efficacy in comorbid conditions, and dosing flexibility.
- Market Expansion: Accelerate approval in emerging markets and pursue indication extensions.
- Patient-Centric Approaches: Emphasize safety profiles to differentiate from traditional sedatives.
- Regulatory Engagement: Continued dialogue with agencies to support label expansions.
- Data Generation: Invest in post-marketing studies to reinforce safety and efficacy claims.
Key Takeaways
- Clinical Development: DAYVIGO maintains a robust clinical trial pipeline emphasizing long-term safety and efficacy in diverse populations.
- Market Performance: Currently holds approximately 15% of the insomnia therapeutics market, with significant growth potential driven by its safety profile.
- Competitive Positioning: Differentiates through better tolerability and longer half-life, but faces price competition and saturation.
- Market Growth: Estimated to reach USD 4.5 billion globally by 2028 with a CAGR of over 32%, primarily driven by North America, Europe, and Asia-Pacific markets.
- Strategic Focus: Expanding indications, post-market surveillance, and regional penetration are critical to maximizing market share.
FAQs
Q1: How does DAYVIGO compare safety-wise to other insomnia drugs?
A1: DAYVIGO exhibits a favorable safety profile, with lower incidences of next-day drowsiness, cognitive impairment, and dependency compared to benzodiazepines and some orexin antagonists like suvorexant.
Q2: What are the primary barriers to market expansion for DAYVIGO?
A2: Key barriers include high pricing, competition from generics, regulatory approval timelines in emerging markets, and limited awareness among clinicians.
Q3: Are there ongoing efforts to extend DAYVIGO’s indications?
A3: Yes, clinical trials are exploring efficacy in elderly populations, comorbid psychiatric conditions, and potential use in shift work disorder.
Q4: What are the main competitors, and how does DAYVIGO differentiate itself?
A4: Main competitors include suvorexant (Belsomra) and traditional sedatives. DAYVIGO’s differentiators include its dual orexin receptor antagonism, longer half-life, and positive safety profile.
Q5: What is the outlook for DAYVIGO in Asian markets?
A5: Growing acceptance due to aging populations and unmet needs suggests strong potential, especially with localized regulatory approvals and tailored marketing strategies.
References
[1] MarketsandMarkets. (2022). Insomnia Therapeutics Market.
[2] IQVIA. (2022). Global Sleep Disorder Medications Market Data.
[3] FDA. (2019). Approval Letter for DAYVIGO.
[4] European Medicines Agency. (2021). Market Authorization for Lemborexant.
[5] Eisai Co., Ltd. Corporate Reports. (2022). Annual Report and Clinical Trial Updates.
